STOCK TITAN

BIOLASE Hosts Nearly 400 Dental Professionals During Webinar On Landmark Study On Lasers And Managing Periodontitis

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

BIOLASE, Inc. (NASDAQ: BIOL) hosted a panel discussion with nearly 400 dental professionals to review a landmark study from the McGuire Institute. The study compared BIOLASE's REPAIR Perio laser protocol to traditional periodontal flap surgery for managing periodontitis. Key findings highlighted superior patient-related outcomes, including less bruising, swelling, and pain with laser treatment, in addition to faster procedure times. The event reflects growing enthusiasm in the dental community regarding laser treatments, indicating potential for future growth in BIOLASE's market presence.

Positive
  • Nearly 400 dental professionals attended the webinar, indicating strong interest in the REPAIR Perio protocol.
  • Superior patient outcomes were reported, including less pain and faster recovery times compared to traditional surgery.
  • The study aligns with the American Academy of Periodontology's Best Evidence Consensus recommendations, enhancing credibility.
Negative
  • None.

FOOTHILL RANCH, Calif., Sept. 15, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it hosted nearly 400 dental professionals last Thursday evening during a panel discussion on the NEW Journal of Periodontology landmark study from the McGuire Institute comparing periodontal flap surgery to BIOLASE's REPAIR Perio laser protocol in managing periodontitis.

Members of the investigating team, Dr. Rick Heard and Dr. Donald Clem, along with a panel of Periodontists reviewed the study's design, protocol development, study findings including superior patient related outcomes, and the clinical implications moving forward for dental practices.

The learning objectives of the webinar were to:

  • Understand the American Academy of Periodontology's Best Evidence Consensus recommendations for studies and how this study meets them
  • Learn the advantages of minimally invasive REPAIR Perio laser protocol for patient reported outcomes, compared to periodontal flap surgery, and
  • Determine how all tissue laser technology can enhance today's periodontal practice

Superior patient related outcomes and periondist findings included:

  • Patients experienced less bruising, swelling and pain with the REPAIR Perio laser treatment compared to MIST
  • Periodontists that were involved in the study reported faster procedure times compared to periodontal flap surgery

"We are excited that we were able to bring together so many dental professionals to discuss the landmark study performed by The McGuire Insititute and the superior patient reported outcomes of Waterlase-assisted treatment of periodontitis," commented Todd Norbe, President and Chief Executive Officer of BIOLASE.  "The recently published results of the study and the benefits of our REPAIR Perio laser protocol have generated significant enthusuiasm within the periodontal community and we look forward to doing more events like this in the future."

About BIOLASE, Inc.

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine.  BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals.  BIOLASE's proprietary laser products incorporate approximately 261 patented and 52 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times.  BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients.  BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications.  BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world.  Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biolase-hosts-nearly-400-dental-professionals-during-webinar-on-landmark-study-on-lasers-and-managing-periodontitis-301130932.html

SOURCE BIOLASE, Inc.

FAQ

What are the key findings from the BIOLASE panel discussion on September 15, 2020?

The panel discussion presented superior patient outcomes with the REPAIR Perio laser protocol compared to traditional periodontal flap surgery.

How does the REPAIR Perio laser protocol benefit patients?

Patients reported less bruising, swelling, and pain, along with faster recovery times.

What was the purpose of BIOLASE's webinar hosted on September 15, 2020?

The webinar aimed to discuss the landmark study on lasers and managing periodontitis, focusing on patient outcomes.

What does the McGuire Institute study indicate about BIOLASE's laser technology?

The study demonstrates the effectiveness of BIOLASE's REPAIR Perio laser protocol in treating periodontitis, suggesting a shift towards minimally invasive treatments.

BIOLASE INC

OTC:BIOL

BIOL Rankings

BIOL Latest News

BIOL Stock Data

2.39M
33.40M
0.3%
6.56%
5%
Medical Devices
Dental Equipment & Supplies
Link
United States of America
FOOTHILL RANCH